Search

Your search keyword '"Toplak H"' showing total 326 results

Search Constraints

Start Over You searched for: Author "Toplak H" Remove constraint Author: "Toplak H"
326 results on '"Toplak H"'

Search Results

1.  Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group)

2. Characteristics and management of individuals with familial hypercholesterolemia in Austria – Data from the national FH-registry

3. Lipid management in patients with high and very high cardiovascular risk: Data from routine clinical practice in Europe (SANTORINI study)

4. Association of branched-chain amino acids with mortality risk in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study

6. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

7. Metabolismus

8. Neue AHA- und ACC-Leitlinie zur Risikoreduktion von Herz-Kreislauf-Erkrankungen durch Cholesterinsenkung: Stellungnahme der D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V., der Österreichischen Atherosklerose Gesellschaft und der Arbeitsgruppe Lipide und Atherosklerose (AGLA) der Schweizer Gesellschaft für Kardiologie

10. Short-term effects of intensive LDL-cholesterol lowering with alirocumab on vascular structure and function

11. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe:methodology and rationale for the multinational observational SANTORINI study

14. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions

15. Obesity and cardiovascular risk: A call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: Part A: Mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment

29. Evolocumab and clinical outcomes in patients with cardiovascular disease

30. European practical and patient-centred guidelines for adult obesity management in primary care

31. Erratum zu: Neue AHA- und ACC-Leitlinie zur Risikoreduktion von Herz-Kreislauf-Erkrankungen durch Cholesterinsenkung. Stellungnahme der D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V., der Österreichischen Atherosklerose Gesellschaft und der Arbeitsgruppe Lipide und Atherosklerose (AGLA) der Schweizer Gesellschaft für Kardiologie

32. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

33. Obesity and cardiovascular risk: A call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: Part A: Mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment

34. Obesity and cardiovascular risk: A call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: Part B: Obesity-induced cardiovascular disease, early prevention strategies and future research directions

35. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

37. Das pharmakologische Management von Adipositas

41. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

44. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and heart failure

46. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

47. Ernährung und Lebensstilmedizin beim alten Menschen

48. Abschreiben erlaubt – die Genese des österreichischen Lernzielkatalogs für ärztliche Fertigkeiten und dessen geplante Operationalisierung

49. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing

Catalog

Books, media, physical & digital resources